BC Week In Review | Feb 29, 2016
Clinical News

Dapivirine Vaginal Ring: Phase III data

Top-line data from the double-blind, South African and Ugandan Phase III Ring Study in 1,959 HIV-negative women ages 18-45 showed that a once-monthly vaginal ring containing 25 mg dapivirine reduced the incidence of HIV infection...
BC Week In Review | Feb 29, 2016
Clinical News

Dapivirine Vaginal Ring: Phase III data

Top-line data from the double-blind Phase III ASPIRE trial in 2,629 HIV-negative women ages 18-45 in Malawi, South Africa, Uganda and Zimbabwe showed that a once-monthly vaginal ring containing 25 mg dapivirine reduced the incidence...
BC Week In Review | Jun 14, 2010
Clinical News

Dapivirine: Phase I/II started

The International Partnership for Microbicides began a placebo-controlled, African Phase I/II (IPM 015) trial to evaluate a dapivirine vaginal ring in 280 women. The ring releases 25 mg dapivirine over 28 days. The non-profit organization...
Items per page:
1 - 3 of 3